Keyphrases
Acute Diarrhea
25%
Age Groups
27%
Bacterial Colony
25%
Bilistick
25%
Case Fatality Rate
25%
Chloramphenicol
25%
Comorbidity
16%
Conjunctiva
25%
COVID-19 Cases
25%
COVID-19 Data
18%
COVID-19 in children
12%
COVID-19 Pandemic
25%
Critically Ill
25%
Data Registry
50%
Dysbiosis
12%
Eye Ointment
25%
Gestational Age
28%
Growth Trajectory
25%
Gut Microbiota
25%
Incomplete Information
25%
Indonesia
83%
Indonesian
80%
L-type Fatty Acid-binding Protein
25%
Length-weight
16%
Meta-analysis
12%
Meta-analysis of Randomized Controlled Trials
25%
Methods Section
12%
Ministry of Health
12%
National Survey
25%
Neonatal Indirect Hyperbilirubinemia
25%
Neonate
13%
Ophthalmic Solutions
25%
Parent Perspectives
25%
Pediatric
53%
Pediatric COVID-19
50%
Phototherapy
50%
Point-of-care
25%
Postnatal Growth Failure
25%
Povidone-iodine (PVP-I)
25%
Preterm Infants
100%
Preterm Neonates
27%
Protein Use
25%
School Reopening
25%
Systematic Meta-analysis
25%
Test Agreement
25%
Total Bilirubin
43%
Transcutaneous Bilirubin
25%
Transcutaneous Bilirubinometer
15%
Ursodeoxycholic Acid
25%
Weight-for-age z Score
17%
Medicine and Dentistry
Acute Diarrhea
25%
Adjuvant Therapy
6%
Adverse Event
5%
Bacterial Growth
5%
Bacterium Colony
25%
Bifidobacterium
12%
Bilirubin
18%
Case Fatality Rate
8%
Chloramphenicol
25%
Clostridium
9%
Colony Forming Unit
5%
Comorbidity
7%
Conjunctivitis
5%
Cost-Effectiveness Analysis
5%
COVID-19
75%
Developmental Milestone
12%
Diarrhea
6%
Diseases
6%
Dysbiosis
12%
Enterobacter
6%
Eye Ointment
25%
Gram-Negative Bacteria
5%
Gram-Positive Bacteria
10%
Growth, Development and Aging
12%
Gut Microbiota
25%
Health Care
12%
Hearing Impairment
12%
Hyperbilirubinemia
25%
Lactobacillus
6%
Meta-Analysis
25%
Neonatal Infant
31%
Neonatal Jaundice
12%
Neonate
6%
Newborn Ophthalmia
5%
Pediatrics
53%
Phototherapy
25%
Placebo
12%
Povidone Iodine
25%
Premature Labor
25%
Prematurity
25%
Probiotics
25%
Prospective Cohort Study
12%
Random Effects Model
6%
Randomized Controlled Trial
30%
Subgroup Analysis
6%
Survival Rate
12%
Systematic Review
25%
Treatment Group
6%
Ursodeoxycholic Acid
25%
Visual Impairment
12%